We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Umbilical Cords Tapped as Rich Source of Noncontroversial Stem Cells

By LabMedica International staff writers
Posted on 31 Dec 2009
To capitalize on the potential of umbilical cords to be a rich source of noncontroversial stem cells, a team of cell biologists has conducted an in-depth in situ study to map the location of stem cell precursors in the cords and to develop straightforward methods for the isolation and expansion of these cells.

Investigators at the University of Pittsburgh School of Medicine (PA, USA) analyzed sections of 61-cm-long human umbilical cords that had been donated for research. More...
For this purpose, they developed a novel in situ assay system that permitted them to analyze cells in the Wharton's jelly, the soft, hyaluronic acid rich, jelly-like intercellular substance of the umbilical cord as well as in the cords' blood vessel walls. They were seeking cells that expressed any of several mesenchymal stromal cell (MSC) markers (CD44, CD73, CD90, and CD105) as well as several progenitor and endothelial cell markers (CD146, CD34, and CD144).

They reported in the December 2009 online edition of the Journal of Biomedicine and Biotechnology that they had succeeded in determining the frequency and location of the markers and in identifying various isolation methods which yielded different cell types from the whole human umbilical cord. They showed that it was possible to isolate endothelial cells by classical methods as well as describing another method that did not require tedious removal of vessels. This method yielded a population of cells that expressed MSC markers and was capable of differentiation into multiple cell types. In addition, they developed a culturing scheme that allowed quantitative expansion of umbilical cord stromal cells that displayed a remarkably stable phenotype.

"Our experiments indicate also that at least 21 million stem cells, and possibly as many as 500 million, could be banked from a single umbilical cord after the birth of a baby," said senior author Dr. Bridget M. Deasy, assistant professor of orthopedic surgery at the University of Pittsburgh School of Medicine. "So, the cord could become an accessible source of a multitude of stem cells that overcomes many of the restrictions, such as limited quantity as well as donor age and donor sex issues that come with other adult stem cell populations."

Related Links:
University of Pittsburgh School of Medicine



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.